SynOx Therapeutics raised an additional funding in a Series B extension led by Gilde Healthcare, bringing total capital to $92 million to support the Phase 3 TANGENT trial of emactuzumab.
SynOx Therapeutics raised an additional funding in a Series B extension led by Gilde Healthcare, bringing total capital to $92 million to support the Phase 3 TANGENT trial of emactuzumab.
10/30/24, 11:14 AM
Location
dublinMoney raised
$92 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
Bioqube Ventures, Health Cap, Forbion, Gilde Healthcare
SynOx Therapeutics Limited has announced the final close of its Series B financing, now totaling $92 million. The funding will support a registrational Phase 3 clinical trial for emactuzumab, targeting Tenosynovial Giant Cell Tumour.
Company Info
Location
dublin, dublin, ireland
Additional Info
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.